Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 4,778 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Cancers Clear all

Conditions: Hematuria, Dysuria, Bladder Cancer
Interventions: Not listed
Lead sponsor: Medical Diagnostic Laboratories, LLC; Industry
Eligibility: 25 Years and older
Enrollment: 1,115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Adenocarcinoma
Interventions: ING-1(heMAb); Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lymphoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Scottsdale, Arizona • Miami, Florida • Tampa, Florida + 11 more

Conditions: Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
Interventions: Plasma exchange, Daratumumab; Procedure · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: I-131-CLR1404; Drug
Lead sponsor: Cellectar, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more

Conditions: Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions: CP-383; Drug
Lead sponsor: Tasca Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more

Conditions: Early Detection of Cancer, Cancer
Interventions: MCED, SOC; Other
Lead sponsor: GRAIL, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 14,633 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more

Conditions: Multiple Myeloma
Interventions: Imetelstat Sodium (GRN163L); Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Detroit, Michigan • New York, New York • Seattle, Washington

Conditions: Urinary Bladder Neoplasms
Interventions: Lenalidomide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Bethesda, Maryland • New York, New York • Salt Lake City, Utah

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Gilteritinib, Ivosidenib, Enasidenib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Malignant Neoplasms
Interventions: No intervention; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Houston, Texas

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 20
States / cities: Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: tocladesine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 1999
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, BIRADS 3, BIRADS 4, BIRADS 5
Interventions: DCE-MRI and DWI; Procedure
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions: deferasirox; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Infection, Multiple Myeloma
Interventions: ciprofloxacin, ofloxacin, 160 mg trimethoprim and 800 mg sulfamethoxazole; Drug
Lead sponsor: Gary Morrow; Other
Eligibility: 18 Years to 120 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 43
States / cities: Mobile, Alabama • Cedar Rapids, Iowa • Ottumwa, Iowa + 32 more

Conditions: Wilms Tumor
Interventions: Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection, Surgical Resection, Partial Nephrectomy; Device · Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Myelogenous Leukemia
Interventions: Nexavar (Sorafenib, BAY43-9006); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 36
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 33 more

Conditions: Solid Tumors
Interventions: Atezolizumab, Cergutuzumab Amunaleukin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • New York, New York • Nashville, Tennessee

Search by objective public record fields.

Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

REFLECTION: A Clinical Practice Learning Program for Galleri®

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

A Multi Center Study of Sexual Toxicities After Radiotherapy

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Familial Investigations of Childhood Cancer Predisposition

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors